Todays News: Companies Of Interest!

M2 PRESSWIRE-9 May 2007-Businessnetwire.us: Todays News: Companies Of Interest!(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:09052007

New York, NY - HealthSonix, Inc. (OTC: HSXI); HEALTHeUNIVERSE Inc. (PINKSHEETS: HLUN); Aastrom Biosciences, Inc. (Nasdaq: ASTM); StemCells, Inc. (NASDAQ: STEM)

BusinessNetWire is an affiliate of Stock Profiler.US. To receive your FREE subscription to our newsletter, please visit: http://www.stockprofiler.us.

HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S)

HealthSonix, Inc. closed at $36 Tuesday, trading 663,705 shares.

Earlier today, HealthSonix, Inc. announced that it will increase its online presence on May 21, 2007 by launching a new web site dedicated to people who suffer from the pain associated with arthritis: www.MyArthritisStore.com

It is estimated that 21.5% of the population of the US is afflicted with arthritis or other rheumatic diseases. With an estimated 1.1 billion internet users worldwide, and Americans spending over $80 billion annually on arthritis treatment, it would seem that HealthSonix internet offering is coming at a most opportune time.

"Not everyone in the world can attend one of our treatment facilities, hence we will make available, online, products that can be used at home or while traveling," stated Dieter Doederlein Vice President of Corporate Development. "The cornerstone of our medical breakthrough remains medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain, but there are many new, state of the art products around the world that are not yet available in retail stores in North America and our objective is to bring as many as feasible to our online customers over the years to come. "

According to today's announcement, the first products to be offered online are the state of the art, self-administered enSonix@home medical device that is particularly effective in treating the pain of arthritis, fibromyalgia, low back pain, and soft tissue injuries. The second product to be offered is ZingiberRx, a new pain relieving cream.

The launch of MyArthritisStore.com will be accompanied by direct to consumer advertising, both in standard arthritis publications and over the internet, and a major public relations program," added Doederlein.

About HealthSonix, Inc. (PINKSHEETS: HSXI)

Healthsonix Inc. is a publicly traded medical technology company, whose core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves have been shown to be 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects

HealthSonix has two operating divisions:

The Healthcare Services Division provides treatment programs administered by licensed healthcare professionals and certified AquaSonix Therapists in clinical settings (Arthritis Treatment Centers of America) and in warm water swimming pools (AquaSonix Therapy Centers).

The Medical Products Division markets medical devices and health related products for personal use (enSonix@home, Health Supplements) and uses a variety of direct-to-customer distribution channels.

More information regarding HealthSonix and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

HEALTHeUNIVERSE Inc. (PINKSHEETS: HLUN)

HEALTHeUNIVERSE, Inc. closed at $.05 Tuesday, trading 50,698 shares.

According to a news release from WallStreetCorner.com yesterday, HEALTHeUNIVERSE, Inc. is a new Special Situation there at www.WallStreetCorner.com)

The release stated that HLUN is engaged in R&D & commercialization of regenerative medicine therapies utilizing non- embryonic adult stem cells for use in plastic & reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, & wound care. It strives to be the first to commercialize the use of regenerative medicine in highly lucrative plastic & reconstructive surgery applications, & to develop therapeutic uses in disease related commercial applications.

With its focus on adapting emerging non-embryonic stem cell & regenerative medicine techniques for use in plastic & reconstructive surgical procedures, HLUN has developed a unique approach to the utilization of advances in biotechnology. According to the company, there are no competitors presently who have commercialized the use of non-embryonic stem cell therapy applications for use in the fields of plastic, reconstructive, & cosmetic surgery. This could translate into a virtually open field for HLUN in a dynamic & robust sector.

As the population ages, increasing demands are being placed on the healthcare industry to find new & more effective solutions. In just the U.S., the projected market for regenerative medicine is estimated at $100 billion (Source: U.S. Dept. of Health & Human Services). According to the 2000 U.S. Census figures, 35 million Americans were aged 65 years of age or older, & that figure is expected to double by 2040. Globally, the biotechnology market is forecast to reach $180.5 billion in 2009, an increase of 58.2% in just five years (Source: Datamonitor).

The Adult Stem Cell R&D Center

HLUN is building the Adult Stem Cell Research & Development Center in Singapore with an alliance & support from the Economic Development Board of Singapore (EDB). Its focus is to collaborate with other R&D facilities in Asia in preparation for clinical trials.

Our Profile includes the CEO's summary of recent accomplishments, an explanation of what stem cells are, a list of patents, a treatise on regenerative medicine, market statistics, background of management, & recent news -- this situation is unique -- I suggest that you check the Profile.

Yesterday's news release stated WallStreetCorner.com's opinion:

"We feel that this situation has exceptional long-term appreciation potential. While it has competition from several large companies in the stem cell field, & must go through a long process of clinical trials, the future certainly looks attractive to us. We are impressed with management's description of its Euphora product. Management comment: Botox sales totaled $564 million last year in the U.S. alone. The drug, which helps smooth out wrinkles by paralyzing the underlying facial muscles, is generally administered through a needle. Not only is the HealtheUniverse product superior in that it utilizes the patients' own cells instead of a toxin, it also lasts for the life of the patient instead of the current 3-6 month application. If successful, we believe it can compete favorably against all existing cosmetic surgery products, including Botox. We project the company has the potential to launch Euphora for fine lines & wrinkles this year & can quickly penetrate over 2% of the total market. With an estimated cost of $700/patient, we arrive at potential revenue of approximately $12.9 million by 2009. We believe that approval of Euphora for cosmetic surgery products should give the company strong validation for its stem cell technology. We would expect further upside to our revenue estimates if positive news from ongoing & future clinical programs evaluating our other products in the areas of wound care & orthopedics are announced.'"

About HEALTHeUNIVERSE Inc. (PINKSHEETS: HLUN)

HEALTHeUNIVERSE Inc. is engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in disease related commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/Aastrom Biosciences, Inc. (Nasdaq: ASTM)

Aastrom Biosciences, Inc. closed at $1.49 Tuesday, trading 4,158,300 shares.

Aastrom Biosciences, Inc., yesterday announced financial results for the third fiscal quarter that ended March 31, 2007. The Company also reported clinical milestones achieved since January of 2007: Total revenues for the quarter and nine months ended March 31, 2007, consisting of product sales and grant funding, were $258,000 and $520,000, respectively, compared to $238,000 and $535,000 for the same periods in fiscal year 2006. Total costs and expenses for the quarter and nine months ended March 31, 2007 increased to $5,180,000 and $14,766,000, respectively, from $5,037,000 and $13,467,000 for the same periods in fiscal year 2006.

About Aastrom Biosciences, Inc. (Nasdaq: ASTM)

Aastrom Biosciences, Inc., founded in 1989 and headquartered in Ann Arbor, Michigan, develops autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) technology. Its TRC-based products are a unique cell mixture containing stem and progenitor cell populations, produced from a small amount of bone marrow taken from the patient. TRC-based products are under clinical trials for bone regeneration (osteonecrosis of the femoral head, long bone fractures, and spine fusion) and vascular regeneration (critical limb ischemia) applications. The company is also developing programs for TRC-based therapies to address cardiac and neural regeneration indications. TRCs have received Orphan Drug Designation from the U.S. Food and Drug Administration for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart.

StemCells, Inc. (NASDAQ: STEM)

StemCells, Inc. closed at $2.55 Tuesday, trading 1,318,400 shares.

On Monday, StemCells, Inc. reported its financial results for the first quarter of 2007.

The Company reported a net loss of $4,620,000, or $0.06 per share, for the first quarter ended March 31, 2007, compared to a net loss of $4,193,000, or $0.06 per share, for the first quarter of 2006. The increase in net loss from 2006 to 2007 was primarily attributable to an increase in operating expenses due to the expansion of the Company's cell manufacturing, process development and clinical operations. The increase in expenses was partially offset by an increase in other income primarily attributable to a realized gain of $718,000 from the sale of approximately 5.3 million shares of common stock of ReNeuron Group plc ("ReNeuron") held as marketable securities, $550,000 in other income recognized upon the receipt of additional ReNeuron shares in connection with a license and settlement agreement, and higher interest income attributable to a higher average cash balance and higher yield on investments in 2007. Net cash used in operating activities for the first quarter in 2007 was $5,252,000, compared with $4,263,000 for the same quarter in 2006. Cash and cash equivalents were $50,922,000 at March 31, 2007, compared with $30,876,000 at March 31, 2006.

Subsequent to the end of the first quarter, the Company sold approximately 820,000 shares of common stock for which the Company received net proceeds of approximately $2,289,000. In addition, a warrant to purchase an aggregate of 575,658 shares of the Company's common stock at $1.90 per share was exercised. The Company issued 575,658 shares of its common stock and received proceeds of approximately $1,094,000. Pro forma cash and cash equivalents at March 31, 2007, assuming these transactions had occurred at March 31, 2007, would have been $54,305,000.

About StemCells, Inc. (NASDAQ: STEM)

StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the nervous system, liver and pancreas. The Company's programs seek to repair or repopulate neural, liver or other tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of the human neural stem cell. The human neural stem cells are expandable into cell banks for therapeutic use, which offers the potential of using normal, non-genetically modified cells as cell-based therapies. StemCells is currently conducting a Phase I clinical trial of its proprietary human neural stem cells (HuCNS-SC(TM)) as a treatment for neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative disease that affects infants and young children. StemCells has approximately 50 U.S. and 100 non-U.S. patents. Further information about the Company is available on its web site at: www.stemcellsinc.com.

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BusinessNetwire.US affiliates has not been compensated for services rendered; BusinessNetwire.US affiliates is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.businessnetwire.us) (disclaimers).

CONTACT: BusinessNetwire.USe-mail: info@ businessnetwire.usWWW: http://www.businessnetwire.us/

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).